Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA-seq analysis of S100A16-mediated alternative splicing in lung adenocarcinoma under oxidative stress

ABSTRACT: Lung adenocarcinoma (LUAD) cells develop adaptive mechanisms to survive high oxidative stress in the tumor microenvironment. This study aims to elucidate the role of S100A16, a calcium-binding protein, in regulating mitochondrial quality control and oxidative stress resistance. We performed polyA-enriched mRNA sequencing on human lung adenocarcinoma A549 cells with stable knockdown of S100A16, hnRNPM (a splicing factor identified as S100A16 interactor) or MagoHB (a negative control interactor), with or without 100μM H₂O₂ treatment for 2 hours (3 biological replicates per group). Transcriptomic analysis revealed that S100A16 translocates to the nucleus under oxidative stress and interacts with hnRNPM to modulate alternative splicing of mitochondrial genes (e.g., LETMD1), thereby maintaining mitochondrial morphology, membrane potential and respiratory function. These data provide mechanistic insights into S100A16 as a potential therapeutic target for LUAD.

ORGANISM(S): Homo sapiens

PROVIDER: GSE330179 | GEO | 2026/08/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

mRNA-seq analysis of S100A16-mediated alternative splicing in lung adenocarcinoma under oxidative stress

Project description:mRNA-seq analysis of S100A16-mediated alternative splicing in lung adenocarcinoma under oxidative stress

| PRJNA1463067 | ENA

Effect of depletion of S100A16 on gene expression during lipid accumulation of primary hepatocytes

Project description:Alcoholic liver disease (ALD) encompasses conditions ranging from simple steatosis to cirrhosis and even liver cancer. It has gained significant global attention in recent years. Despite this, effective pharmacological treatments for ALD remain elusive, and the core mechanisms underlying the disease are not yet fully comprehended. S100A16, a newly identified calcium-binding protein, is linked to lipid metabolism. Our research has discovered elevated levels of the S100A16 protein in both serum and liver tissue of ALD patients. A similar surge in hepatic S100A16 expression was noted in a Gao-binge alcohol feeding mouse model. S100a16 knockdown alleviated ethanol-induced liver injury, steatosis and inflammation. Conversely, S100a16 transgenic mice showed aggravating phenomenon. Mechanistically, we identify mesencephalic astrocyte-derived neurotrophic factor (MANF) as a regulated entity downstream of S100a16 deletion. MANF inhibited ER-stress signal transduction induced by alcohol stimulation. Meanwhile, MANF silencing suppressed the inhibition effect of S100a16 knockout on ethanol-induced lipid droplets accumulation in primary hepatocytes. Our data suggested that S100a16 deletion protects mice against alcoholic liver lipid accumulation and inflammation dependent on upregulating MANF and inhibiting ER stress. This offers a potential therapeutic avenue for ALD treatment.

2023-09-26 | GSE243683 | GEO

S100a16 deficiency prevents liver fibrosis via inhibiting C-X-C motif chemokine receptor 4 expression

Project description:Liver fibrosis has been implicated in the pathogenesis of various liver disease. Thus far, there is still no effective intervention means for this process. Recently, we have demonstrated that S100A16 participated in liver lipid accumulation and renal fibrosis. Therefore, we hypothesized that S100A16 took a critical role in liver fibrosis. S100a16 transgenic and knockdown mice were generated and stimulated with carbon tetrachloride, bile duct ligation and methionine choline deficiency diet. Alterations of gene expression in hepatic stellate cells from wild type and S100a16+/- mice were investigated by transcriptome sequencing. S100A16 expression levels in liver tissue of patients and rodent models of liver fibrosis were markedly increased. S100a16 transgenic mice showed spontaneous liver fibrosis after normal feeding for 6 months. On the contrary, silencing of S100a16 exhibited obvious protective effect against liver fibrosis caused by different stimulations. Meanwhile, results showed that deletion of S100a16 significantly inhibited hepatic stellate cells (HSCs) activation cultured in fetal bovine serum contained medium. RNA sequencing results revealed that mechanistically, C-X-C motif chemokine receptor 4 (Cxcr4) participated in the process of S100a16 in liver fibrosis. Knockdown of S100a16 inhibited Cxcr4 expression through augmenting P53 expression. SDF-1α/CXCR4-dependent extracellular signal-regulated kinase 1/2 and Akt phosphorylation mediated the effects of S100a16 on α-smooth muscle actin expression and HSCs activation. These data indicate that S100a16 deficiency prevents liver fibrosis by inhibiting Cxcr4 expression. Targeting S100A16 may provide insights into the pathogenesis of liver fibrosis and pave the way for developing strategies for liver fibrosis-related diseases prevention and treatment.

2022-03-25 | GSE199294 | GEO

Proteomic analysis in S100A16-overexpressed human gastric cancer cells lines

Project description:Our studies reveal that S100A16 overexpression triggers GC cells proliferation and migration both in vivo and in vitro; by contrast, S100A16 knockdown restricts the speed of GC cells growth and mobility. Proteomic analysis results reveal a large S100A16 interactome, which includes ZO-2 (Zonula Occludens-2), a master regulator of cell-to-cell tight junction

2022-02-17 | PXD028022 | Pride

PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression

Project description:Background: The identification of cancer driver genes from sequencing data has been crucial in deepening our understanding of tumor biology and expanding targeted therapy options. However, apart from the most commonly altered genes, the mechanisms underlying the contribution of other mutations to cancer acquisition remain understudied. Leveraging on our whole-exome sequencing of the largest Asian lung adenocarcinoma (LUAD) cohort (n=302), we now functionally assess the mechanistic role of a novel driver, PARP4. Methods: In vitro and in vivo tumorigenicity assays were used to study the functional effects of PARP4 loss and mutation in multiple lung cancer cell lines. Interactomics analysis by quantitative mass spectrometry was conducted to identify PARP4’s interaction partners. Transcriptomic data from cell lines and patient tumors were used to investigate splicing alterations. Results: PARP4 depletion or mutation (I1039T) promotes the tumorigenicity of KRAS- or EGFR-driven lung cancer cells. Disruption of the vault complex, with which PARP4 is commonly associated, did not alter tumorigenicity, indicating that PARP4’s tumor suppressive activity is mediated independently. The splicing regulator hnRNPM is a potentially novel PARP4 interaction partner, the loss of which likewise promotes tumor formation. hnRNPM loss results in splicing perturbations, with a propensity for dysregulated intronic splicing that was similarly observed in PARP4 knockdown cells and in LUAD cohort patients with PARP4 copy number loss. Conclusions: PARP4 is a novel modulator of lung adenocarcinoma, where its tumor suppressive activity is mediated not through the vault complex – unlike conventionally thought, but in association with its novel interaction partner hnRNPM, thus suggesting a role for splicing dysregulation in LUAD tumorigenesis.

2024-04-02 | PXD050844 | Pride

Identification and Functional Analysis of MYEOV, KCNN4, S100A16 and DDX60L in Pancreatic Ductal Adenocarcinoma

Project description:siRNA of MYEOV, KCNN4, S100A16 and DDX60L treated MiaPaCa2 and PANC-1 cells were used for RNA-seq to identify the transcriptomic alterations.

2021-04-06 | GSE171486 | GEO

Proteogenomic Characterization Reveals Tumorigenesis and Progression of Lung Adenocarcinoma Manifested as Subsolid Nodules

Project description:Lung adenocarcinoma (LUAD) radiologically displayed as subsolid nodules (SSNs) is prevalent. However, precise clinical management of SSNs requires thorough understanding of its tumorigenesis and progression. Here, we analyzed 66 LUAD displayed as SSNs covering 3 histological stages including adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC) by incorporating genomics, proteomics, phosphoproteomics and glycoproteomics. Intriguingly, cholesterol metabolism is aberrantly regulated in the preneoplastic AIS stage. Furthermore, sustained endoplasmic reticulum stress was demonstrated to be a hallmark and a reliable biomarker of AIS progression to IAC. Consistently, targeted promotion of ER stress profoundly retarded LUAD progression. Our study provides comprehensive proteogenomic landscape of SSNs, sheds lights on the tumorigenesis and progression of SSNs and suggests preventive and therapeutic strategies for LUAD.

2025-02-10 | PXD046637 | Pride

Identification and Functional Analysis of MYEOV, KCNN4, S100A16 and DDX60L in Pancreatic Ductal Adenocarcinoma

Project description:Identification and Functional Analysis of MYEOV, KCNN4, S100A16 and DDX60L in Pancreatic Ductal Adenocarcinoma

| PRJNA719795 | ENA

Effects of parthenolide on amino acid metabolism and oxidative stress in lung adenocarcinoma based on quantitative proteomic analysis, targeted amino acid metabolomics, network pharmacology, and experimental validation

Project description:Background: Lung adenocarcinoma (LUAD) causes millions of deaths annually worldwide. Parthenolide (PTL), extracted from traditional Chinese herbal medicines, has various biological activities. In this study, we investigated the effects of PTL on amino acid metabolism and oxidative stress in LUAD cells. Methods: This study identified differential proteins and potential mechanisms of action of PTL in LUAD cells through label-free quantitative proteomics and protein-protein interaction networks. Combined with targeted amino acid metabolomics, we confirmed the results of GO and KEGG analyses. On this basis, the potential targets of PTL in LUAD were identified through network pharmacology, molecular simulation docking, and molecular dynamics simulations. Finally, the effects of PTL on amino acid metabolism and oxidative stress in LUAD were verified using in vivo and in vitro experiments. Results: PTL treatment of LUAD cells resulted in significant changes in expression of 157 proteins. GO and KEGG enrichment analyses showed that these proteins were involved in amino acid metabolism and oxidative stress response. Targeted amino acid metabolomics further confirmed that PTL affected amino acid metabolism in LUAD. Network pharmacology, molecular docking, and molecular dynamics simulations identified GCTG as a potential target of PTL in LUAD. Meanwhile, in vitro and in vivo experimental results indicated that PTL targeting GCTG affected the proliferation, amino acid metabolism, and oxidative stress levels of LUAD cells. Conclusion: PTL affects proliferation, amino acid metabolism, and oxidative stress levels of LUAD cells via targeting GCTG. Therefore, our study provides new insights into the prevention and treatment of LUAD with PTL, which may lay the foundation for future research directions

2025-08-18 | PXD067441 |

A novel lncRNA, LUADT1 promotes lung adenocarcinoma proliferation by epigenetic suppression of p27

Project description:Long noncoding RNAs (lncRNAs) are known to regulate the development and progression of various cancers, however, few lncRNAs have been well characterized in lung adenocarcinoma (LUAD). Understanding the expression profile of lncRNAs and protein-coding genes is critical to develop new diagnosis and treatment strategies for LUAD and improving the prognosis of diagnosed patients. Five female LUAD patients with no smoking history were selected to profile lncRNA and protein-coding gene expression with microarrays. Paired tumor tissues and adjacent nontumor tissues were collected and confirmed by pathologists.

2015-03-10 | E-GEOD-66654 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data